Non-Small Cell Lung Cancer: Trends in Stage I Treatment

Share this content:
Radiation therapy in stage I NSCLC improved survival over a period of 10 years.
Radiation therapy in stage I NSCLC improved survival over a period of 10 years.

HealthDay News — For patients with stage I non-small-cell lung cancer (NSCLC), the odds of receiving radiation therapy (RT) or surgery increased from 2000 to 2010, with improved survival during the same period, according to a study published online in the Annals of Thoracic Surgery.

Nirav S. Kapadia, MD, from Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, and colleagues conducted a population-based comparative effectiveness study using Surveillance, Epidemiology, and End Results-18 data from 2000 to 2010 for stage I NSCLC patients. A total of 40,589 patients (62%) underwent surgery, 10,048 (15%) received RT, 2130 (3%) received both surgery and RT, and 11,537 (18%) received neither surgery nor RT.

The researchers found that there was an increase annually in the odds of either receiving definitive RT or undergoing surgery relative to the odds of receiving no treatment (odds ratios, 1.04 and 1.05, for RT and surgery, respectively). The proportion of sublobar resections increased steadily among surgical patients, from 12.9% to 17.9%. Each year there was a 3.5% decrease in the 2-year risk of death for all patients (hazard ratio, 0.965), driven mainly by improved survival for surgical and RT patients (annualized hazard ratios, 0.959 and 0.942, respectively).

"Between 2000 and 2010, stage I NSCLC patients were more likely to receive definitive treatment with either surgery or RT, leading to a decline in the number of untreated patients," the authors write.

Reference

Kapadia NS, Valle LF, George JA, et al. Patterns of treatment and outcomes for definitive therapy of early stage non-small cell lung cancer. Ann Thorac Surg. 2017;104(6):1881-1888. doi:10.1016/j.athoracsur.2017.06.065

Sign Up for Free e-newsletters